Clinical trial · no report yet · Phase 2
ARASEC
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
- NCT05059236 ↗
- Completed
- Bayer
- 11 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 4 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- Darolutamide (BAY1841788, Nubeqa); ADT
- Arms
- Darolutamide+ADT · Experimental
- Enrollment
- 223
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Bayer
- Start
- Nov 4, 2021
- Primary completion
- May 30, 2025
- Results posted
- Yes
- Registry record
- NCT05059236 · updated Sep 15, 2026
Publications
linked from the registry- McKay RR, Ross AE, Preston MA, Gregg JR, Salami SS, Littleton N, Constantinovici N, Srinivasan S, Verholen F, Shore ND. Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients. Future Oncol. 2025 May;21(11):1365-1375. doi: 10.1080/14796694.2025.2482360. Epub 2025 Apr 1. PubMed 40165634